{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T16:10:30Z","timestamp":1791562230233,"version":"4.3.4"},"reference-count":103,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-cardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cardiology"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.jjcc.2023.07.019","type":"journal-article","created":{"date-parts":[[2023,8,3]],"date-time":"2023-08-03T11:36:57Z","timestamp":1691062617000},"page":"74-83","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Implementation of evidence-based heart failure management: Regional variations between Japan and the USA"],"prefix":"10.1016","volume":"83","author":[{"given":"Yumiko Kawakubo","family":"Ichihara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Kohsaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megumi","family":"Kisanuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander Tarlochan Singh","family":"Sandhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masataka","family":"Kawana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jjcc.2023.07.019_bb0005","first-page":"e895","article-title":"2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2023.07.019_bb0010","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1253\/circj.CJ-19-0342","article-title":"JCS 2017\/JHFS 2017 guideline on diagnosis and treatment of acute and chronic heart failure \u2014 digest version \u2014","volume":"83","author":"Tsutsui","year":"2019","journal-title":"Circ J"},{"key":"10.1016\/j.jjcc.2023.07.019_bb0015","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jjcc.2023.07.019_bb0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jchf.2022.08.009","article-title":"Heart failure drug treatment\u2014inertia, titration, and discontinuation: a multinational observational study (EVOLUTION HF)","volume":"11","author":"Savarese","year":"2023","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jjcc.2023.07.019_bb0025","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1001\/jamacardio.2021.4585","article-title":"Evaluation of quality of care for US veterans with recent-onset heart failure with reduced ejection fraction","volume":"7","author":"Sandhu","year":"2022","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jjcc.2023.07.019_bb0030","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jacc.2018.04.070","article-title":"Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF registry","volume":"72","author":"Greene","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jjcc.2023.07.019_bb0035","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1016\/j.jacc.2019.03.464","article-title":"Reasons for lack of improvement in treatment with evidence-based therapies in heart failure","volume":"73","author":"Bozkurt","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jjcc.2023.07.019_bb0040","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.114.001504","article-title":"Persistent recovery of normal left ventricular function and dimension in idiopathic dilated cardiomyopathy during long-term follow-up: does real healing exist?","volume":"4","author":"Merlo","year":"2015","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jjcc.2023.07.019_bb0045","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1161\/CIRCULATIONAHA.113.006855","article-title":"Heart failure with recovered ejection fraction clinical description, biomarkers, and outcomes","volume":"129","author":"Basuray","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2023.07.019_bb0050","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jacc.2020.05.075","article-title":"Heart failure with recovered left ventricular ejection fraction: JACC scientific expert panel","volume":"76","author":"Wilcox","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jjcc.2023.07.019_bb0055","doi-asserted-by":"crossref","unstructured":"Bauersachs J. Heart failure drug treatment: the fantastic four. Eur Heart J 2021;42:681\u20133. https:\/\/doi.org\/https:\/\/doi.org\/10.1093\/eurheartj\/ehaa1012.","DOI":"10.1093\/eurheartj\/ehaa1012"},{"key":"10.1016\/j.jjcc.2023.07.019_bb0060","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s10741-021-10120-x","article-title":"Where are we in 2021 with heart failure with reduced ejection fraction?\u2014current outlook and expectations from new promising clinical trials","volume":"27","author":"D\u0119bska-Koz\u0142owska","year":"2022","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.jjcc.2023.07.019_bb0065","doi-asserted-by":"crossref","first-page":"3505","DOI":"10.1002\/ehf2.13124","article-title":"Heart failure in the last year: progress and perspective","volume":"7","author":"Tomasoni","year":"2020","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.jjcc.2023.07.019_bb0070","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2023.07.019_bb0075","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2023.07.019_bb0080","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1161\/CIRCULATIONAHA.117.032038","article-title":"Canagliflozin for primary and secondary prevention of cardiovascular events: results from the CANVAS program (Canagliflozin cardiovascular assessment study)","volume":"137","author":"Mahaffey","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2023.07.019_bb0085","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2023.07.019_bb0090","doi-asserted-by":"crossref","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, K\u00f8ber L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 2019;381:1995\u20132008. https:\/\/doi.org\/https:\/\/doi.org\/10.1056\/NEJMoa1911303.","DOI":"10.1056\/NEJMoa1911303"},{"key":"10.1016\/j.jjcc.2023.07.019_bb0095","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2023.07.019_bb0100","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1002\/ejhf.1498","article-title":"Initiation of sacubitril\/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study","volume":"21","author":"Wachter","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jjcc.2023.07.019_bb0105","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/s41591-021-01659-1","article-title":"The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial","volume":"28","author":"Voors","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.jjcc.2023.07.019_bb0110","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1056\/NEJM199108013250502","article-title":"A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure","volume":"325","author":"Cohn","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2023.07.019_bb0115","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJM198706043162301","article-title":"Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)","volume":"316","author":"CONSENSUS Trial Study Group","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2023.07.019_bb0120","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure","volume":"325","author":"SOLVD Investigators","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2023.07.019_bb0125","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(03)14282-1","article-title":"Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-overall programme","volume":"362","author":"Pfeffer","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.jjcc.2023.07.019_bb0130","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/S0140-6736(00)04560-8","article-title":"Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial","volume":"357","author":"Dargie","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.jjcc.2023.07.019_bb0135","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1056\/NEJM200105313442201","article-title":"Effect of carvedilol on survival in severe chronic heart failure","volume":"344","author":"Packer","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2023.07.019_bb0140","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1161\/01.CIR.90.4.1765","article-title":"A randomized trial of \u03b2-blockade in heart failure: the cardiac insufficiency bisoprolol study (CIBIS)","volume":"90","author":"Lechat","year":"1994","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2023.07.019_bb0145","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/00132586-200006000-00059","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure","volume":"44","author":"Pitt","year":"2000","journal-title":"Surv Anesthesiol"},{"key":"10.1016\/j.jjcc.2023.07.019_bb0150","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2023.07.019_bb0155","doi-asserted-by":"crossref","unstructured":"Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309\u201321. https:\/\/doi.org\/https:\/\/doi.org\/10.1056\/NEJMoa030207.","DOI":"10.1056\/NEJMoa030207"},{"key":"10.1016\/j.jjcc.2023.07.019_bb0160","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(20)30748-0","article-title":"Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials","author":"Vaduganathan","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jjcc.2023.07.019_bb0165","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","article-title":"Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study","volume":"376","author":"Swedberg","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jjcc.2023.07.019_bb0170","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","article-title":"Vericiguat in patients with heart failure and reduced ejection fraction","volume":"382","author":"Armstrong","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2023.07.019_bb0175","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1253\/circj.CJ-21-0431","article-title":"JCS\/JHFS 2021 guideline focused update on diagnosis and treatment of acute and chronic heart failure","volume":"85","author":"Tsutsui","year":"2021","journal-title":"Circ J"},{"key":"10.1016\/j.jjcc.2023.07.019_bb0180","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1093\/eurheartj\/ehac210","article-title":"Accelerated and personalized therapy for heart failure with reduced ejection fraction","volume":"43","author":"Shen","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jjcc.2023.07.019_bb0185","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1016\/j.amjmed.2019.06.053","article-title":"Early effects of starting doses of enalapril in patients with chronic heart failure in the SOLVD Treatment Trial","volume":"133","author":"Lam","year":"2020","journal-title":"Am J Med"},{"key":"10.1016\/j.jjcc.2023.07.019_bb0190","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.jacc.2005.04.038","article-title":"Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure","volume":"46","author":"Pitt","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jjcc.2023.07.019_bb0195","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1001\/jama.289.6.712","article-title":"Effects of initiating carvedilol in patients with severe chronic heart failure","volume":"289","author":"Krum","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.jjcc.2023.07.019_bb0200","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1161\/CIRCULATIONAHA.114.013748","article-title":"Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure","volume":"131","author":"Packer","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2023.07.019_bb0205","first-page":"353","article-title":"Effect of age and sex on efficacy and tolerability of \u03b2 blockers in patients with heart failure with reduced ejection fraction: individual patient data meta-analysis","author":"Kotecha","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.jjcc.2023.07.019_bb0210","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/S0140-6736(22)02076-1","article-title":"Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial","volume":"400","author":"Mebazaa","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jjcc.2023.07.019_bb0215","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1253\/circj.CJ-15-0514","article-title":"Temporal trends in clinical characteristics, management and prognosis of patients with symptomatic heart failure in Japan \u201cReport from the CHART studies\u201d","volume":"79","author":"Ushigome","year":"2015","journal-title":"Circ J"},{"key":"10.1016\/j.jjcc.2023.07.019_bb0220","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1161\/CIRCULATIONAHA.109.934471","article-title":"Improving evidence-based care for heart failure in outpatient cardiology practices: primary results of the registry to improve the use of evidence-based heart failure therapies in the outpatient setting (IMPROVE HF)","volume":"122","author":"Fonarow","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2023.07.019_bb0225","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1016\/j.jacc.2019.02.015","article-title":"Titration of medical therapy for heart failure with reduced ejection fraction","volume":"73","author":"Greene","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jjcc.2023.07.019_bb0230","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S0195-668X(02)00700-5","article-title":"The EuroHeart failure survey programme - a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment","volume":"24","author":"Komajda","year":"2003","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jjcc.2023.07.019_bb0235","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1093\/eurheartj\/ehi499","article-title":"Under-utilization of evidence-based drug treatment in patients with heart failure is only partially explained by dissimilarity to patients enrolled in landmark trials: a report from the euro heart survey on heart failure","volume":"26","author":"Lenzen","year":"2005","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jjcc.2023.07.019_bb0240","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.jchf.2019.02.001","article-title":"Target dose versus maximum tolerated dose in heart failure: time to calibrate and define actionable goals","volume":"7","author":"Bozkurt","year":"2019","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jjcc.2023.07.019_bb0245","article-title":"Medical therapy for patients with recent-onset heart failure with reduced ejection fraction during the COVID-19 pandemic: insights from the Veteran\u2019s affairs healthcare system","volume":"22","author":"Sandhu","year":"2022","journal-title":"Am Heart J Plus"},{"key":"10.1016\/j.jjcc.2023.07.019_bb0250","doi-asserted-by":"crossref","first-page":"e1008","DOI":"10.1016\/S2214-109X(18)30306-1","article-title":"Prescribing patterns of evidence-based heart failure pharmacotherapy and outcomes in the ASIAN-HF registry: a cohort study","volume":"6","author":"Teng","year":"2018","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.jjcc.2023.07.019_bb0255","doi-asserted-by":"crossref","first-page":"8318","DOI":"10.1038\/s41598-022-12357-4","article-title":"Potential association with malnutrition and allocation of combination medical therapies in hospitalized heart failure patients with reduced ejection fraction","volume":"12","author":"Kawakubo","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.jjcc.2023.07.019_bb0260","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2013-003387","article-title":"Utilisation of preventative health check-ups in the UK: findings from individual-level repeated cross-sectional data from 1992 to 2008","volume":"3","author":"Labeit","year":"2013","journal-title":"BMJ Open"},{"key":"10.1016\/j.jjcc.2023.07.019_bb0265","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/clc.23932","article-title":"Characteristics and health-status outcomes in patients with atrial fibrillation detected via health screening","volume":"46","author":"Yamashita","year":"2023","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.jjcc.2023.07.019_bb0270","unstructured":"Ordinance on Industrial Safety and Health (Order of the Ministry of Labour No. 32 of 1972) in Japan, https:\/\/www.japaneselawtranslation.go.jp\/en\/laws\/view\/3878"},{"key":"10.1016\/j.jjcc.2023.07.019_bb0275","first-page":"e596","article-title":"2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"140","author":"Arnett","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2023.07.019_bb0280","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1056\/NEJMoa2208681","article-title":"Five-year outcomes of the Danish Cardiovascular Screening (DANCAVAS) trial","volume":"387","author":"Lindholt","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2023.07.019_bb0285","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s11897-009-0039-z","article-title":"Pathophysiology of the transition from chronic compensated and acute decompensated heart failure: new insights from continuous monitoring devices","volume":"6","author":"Adamson","year":"2009","journal-title":"Curr Heart Fail Rep"},{"key":"10.1016\/j.jjcc.2023.07.019_bb0290","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4414\/smw.2015.14075","article-title":"Check-up examination: recommendations in adults","volume":"145","author":"Virgini","year":"2015","journal-title":"Swiss Med Wkly"},{"key":"10.1016\/j.jjcc.2023.07.019_bb0295","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1161\/CIRCULATIONAHA.108.783910","article-title":"Transition from chronic compensated to acute d compensated heart failure: pathophysiological insights obtained from continuous monitoring of intracardiac pressures","volume":"118","author":"Zile","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2023.07.019_bb0300","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1161\/CIRCHEARTFAILURE.121.008538","article-title":"Disparity in the setting of incident heart failure diagnosis","volume":"14","author":"Sandhu","year":"2021","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jjcc.2023.07.019_bb0305","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.jchf.2022.11.013","article-title":"Predictors of incident heart failure diagnosis setting: insights from the veterans affairs healthcare system","volume":"11","author":"Tisdale","year":"2023","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jjcc.2023.07.019_bb0310","first-page":"1","article-title":"Trends in survival after a diagnosis of heart failure in the United Kingdom 2000-2017: population based cohort study","volume":"364","author":"Taylor","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.jjcc.2023.07.019_bb0315","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1001\/jama.2013.7588","article-title":"Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial","volume":"310","author":"Ledwidge","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.jjcc.2023.07.019_bb0320","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/bmjopen-2013-003866","article-title":"Barriers to accurate diagnosis and effective management of heart failure have not changed in the past 10 years: a qualitative study and national survey","volume":"4","author":"Hancock","year":"2014","journal-title":"BMJ Open"},{"key":"10.1016\/j.jjcc.2023.07.019_bb0325","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s10741-006-9481-0","article-title":"Diagnosis of heart failure in primary care","volume":"11","author":"Fonseca","year":"2006","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.jjcc.2023.07.019_bb0330","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1038\/s41591-021-01335-4","article-title":"Artificial intelligence\u2013enabled electrocardiograms for identification of patients with low ejection fraction: a pragmatic, randomized clinical trial","volume":"27","author":"Yao","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.jjcc.2023.07.019_bb0335","doi-asserted-by":"crossref","first-page":"e117","DOI":"10.1016\/S2589-7500(21)00256-9","article-title":"Point-of-care screening for heart failure with reduced ejection fraction using artificial intelligence during ECG-enabled stethoscope examination in London, UK: a prospective, observational, multicentre study","volume":"4","author":"Bachtiger","year":"2022","journal-title":"Lancet Digital Health"},{"key":"10.1016\/j.jjcc.2023.07.019_bb0340","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2022.100431","article-title":"Community-based participatory research application of an artificial intelligence-enhanced electrocardiogram for cardiovascular disease screening: a FAITH! Trial ancillary study","volume":"12","author":"Harmon","year":"2022","journal-title":"Am J Prev Cardiol"},{"key":"10.1016\/j.jjcc.2023.07.019_bb0345","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.3390\/diagnostics11101863","article-title":"A machine learning approach for chronic heart failure diagnosis","volume":"11","author":"Plati","year":"2021","journal-title":"Diagnostics"},{"key":"10.1016\/j.jjcc.2023.07.019_bb0350","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.cardfail.2021.08.024","article-title":"Hospitalization for heart failure in the United States, UK, Taiwan, and Japan: an international comparison of administrative health records on 413,385 individual patients","volume":"28","author":"Sundaram","year":"2022","journal-title":"J Card Fail"},{"key":"10.1016\/j.jjcc.2023.07.019_bb0355","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.jacc.2013.11.053","article-title":"The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries","volume":"63","author":"Ambrosy","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jjcc.2023.07.019_bb0360","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.jacc.2021.11.061","article-title":"Variability in coronary artery disease testing for patients with new-onset heart failure","volume":"79","author":"Zheng","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jjcc.2023.07.019_bb0365","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1016\/j.jacc.2003.12.040","article-title":"Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure: results of the initiation management predischarge: process for assessment of carvedilol therapy in heart failure (IMPACT-HF) trial","volume":"43","author":"Gattis","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jjcc.2023.07.019_bb0370","doi-asserted-by":"crossref","first-page":"82.e1","DOI":"10.1016\/j.ahj.2006.10.008","article-title":"Carvedilol use at discharge in patients hospitalized for heart failure is associated with improved survival: an analysis from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF)","volume":"153","author":"Fonarow","year":"2007","journal-title":"Am Heart J"},{"key":"10.1016\/j.jjcc.2023.07.019_bb0375","doi-asserted-by":"crossref","unstructured":"Bhagat AA, Greene SJ, Vaduganathan M, Fonarow GC, Butler J. Initiation, continuation, switching, and withdrawal of heart failure medical therapies during hospitalization. JACC Heart Fail 2019;7:1\u201312. https:\/\/doi.org\/https:\/\/doi.org\/10.1016\/j.jchf.2018.06.011.","DOI":"10.1016\/j.jchf.2018.06.011"},{"key":"10.1016\/j.jjcc.2023.07.019_bb0380","first-page":"2807","article-title":"Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure","volume":"94","author":"Bristow","year":"1996","journal-title":"MOCHA Investig Circ"},{"key":"10.1016\/j.jjcc.2023.07.019_bb0385","first-page":"324","article-title":"Low-dose carvedilol improves left ventricular function and reduces cardiovascular hospitalization in Japanese patients with chronic heart failure: the Multicenter Carvedilol Heart Failure Dose Assessment (MUCHA) trial","volume":"147","author":"Hori","year":"2004","journal-title":"Am Heart J"},{"key":"10.1016\/j.jjcc.2023.07.019_bb0390","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.ijcard.2022.04.020","article-title":"Conventional medical therapy in heart failure patients eligible for the PARADIGM-HF, DAPA-HF, and SHIFT trials","volume":"359","author":"Shoji","year":"2022","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jjcc.2023.07.019_bb0395","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1253\/circrep.CR-19-0080","article-title":"Clinical considerations when introducing sodium-glucose co-transporter 2 inhibition in patients with heart failure","volume":"2","author":"Yazaki","year":"2020","journal-title":"Circ Rep"},{"key":"10.1016\/j.jjcc.2023.07.019_bb0400","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1253\/circrep.CR-21-0068","article-title":"Initial real-world practical experience of sacubitril\/valsartan treatment in Japanese patients with chronic heart failure","volume":"3","author":"Nakamura","year":"2021","journal-title":"Circ Rep"},{"key":"10.1016\/j.jjcc.2023.07.019_bb0405","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1146\/annurev.pharmtox.41.1.815","article-title":"Molecular basis of ethnic differences in drug disposition and response","volume":"41","author":"Xie","year":"2001","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.jjcc.2023.07.019_bb0410","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.ahj.2003.11.004","article-title":"Clinical trials in Japan and the United States","volume":"147","author":"Alexander","year":"2004","journal-title":"Am Heart J"},{"key":"10.1016\/j.jjcc.2023.07.019_bb0415","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1001\/jama.2015.18603","article-title":"Comparison of site of death, health care utilization, and hospital expenditures for patients dying with cancer in 7 developed countries","volume":"315","author":"Bekelman","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.jjcc.2023.07.019_bb0420","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1001\/jamanetworkopen.2021.42279","article-title":"End-of-life preferences in older US adults - bridging the \u201cwhat matters\u201d chasm","volume":"5","author":"Iyer","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jjcc.2023.07.019_bb0425","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1377\/hlthaff.23.3.194","article-title":"Place of death: U.S. trends since 1980: Fewer Americans died in the hospital in 1998 than in 1980, but some racial disparities raise troubling questions","volume":"23","author":"Flory","year":"2004","journal-title":"Health Aff"},{"key":"10.1016\/j.jjcc.2023.07.019_bb0430","doi-asserted-by":"crossref","first-page":"25","DOI":"10.4235\/agmr.21.0003","article-title":"Place of death and density of homecare resources: a nationwide study in Japan","volume":"25","author":"Ikeda","year":"2021","journal-title":"Ann Geriatr Med Res"},{"key":"10.1016\/j.jjcc.2023.07.019_bb0435","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.42273","article-title":"Municipal characteristics of in-home death among care-dependent older Japanese adults","volume":"5","author":"Abe","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jjcc.2023.07.019_bb0440","doi-asserted-by":"crossref","first-page":"e153","DOI":"10.1161\/CIR.0000000000001052","article-title":"Heart disease and stroke statistics-2022 update: a report from the American Heart Association","volume":"145","author":"Tsao","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2023.07.019_bb0445","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.008687","article-title":"9-year trend in the management of acute heart failure in Japan: a report from the National Consortium of Acute Heart Failure Registries","volume":"7","author":"Shiraishi","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jjcc.2023.07.019_bb0450","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.jacc.2010.05.011","article-title":"Quantitative evaluation of drug or device effects on ventricular remodeling as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction: a meta-analytic approach","volume":"56","author":"Kramer","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jjcc.2023.07.019_bb0455","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.3390\/s21072335","article-title":"Clinical update of the latest evidence for cardioMEMS pulmonary artery pressure monitoring in patients with chronic heart failure: a promising system for remote heart failure care","volume":"21","author":"Brugts","year":"2021","journal-title":"Sensors"},{"key":"10.1016\/j.jjcc.2023.07.019_bb0460","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/s41569-021-00522-7","article-title":"Smart wearable devices in cardiovascular care: where we are and how to move forward","volume":"18","author":"Bayoumy","year":"2021","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jjcc.2023.07.019_bb0465","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1161\/CIRCIMAGING.113.000438","article-title":"Myocardial fibrosis as a key determinant of left ventricular remodeling in idiopathic dilated cardiomyopathy: a contrast-enhanced cardiovascular magnetic study","volume":"6","author":"Masci","year":"2013","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.jjcc.2023.07.019_bb0470","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.amjcard.2012.02.054","article-title":"Usefulness of left ventricular end-systolic dimension by echocardiography to predict reverse remodeling in patients with newly diagnosed severe left ventricular systolic dysfunction","volume":"110","author":"Bhat","year":"2012","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jjcc.2023.07.019_bb0475","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.jacc.2018.05.042","article-title":"Dynamic trajectories of left ventricular ejection fraction in heart failure","volume":"72","author":"Lup\u00f3n","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jjcc.2023.07.019_bb0480","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1016\/j.jacc.2010.11.030","article-title":"Prevalence and prognostic significance of left ventricular reverse remodeling in dilated cardiomyopathy receiving tailored medical treatment","volume":"57","author":"Merlo","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jjcc.2023.07.019_bb0485","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.jchf.2019.06.004","article-title":"Imaging, biomarker, and clinical predictors of cardiac remodeling in heart failure with reduced ejection fraction","volume":"7","author":"Aimo","year":"2019","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jjcc.2023.07.019_bb0490","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/nrcardio.2011.172","article-title":"Reverse remodeling in heart failure-mechanisms and therapeutic opportunities","volume":"9","author":"Koitabashi","year":"2012","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jjcc.2023.07.019_bb0495","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.jchf.2017.07.011","article-title":"Effect of sex on reverse remodeling in chronic systolic heart failure","volume":"5","author":"Aimo","year":"2017","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jjcc.2023.07.019_bb0500","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.cardfail.2011.03.005","article-title":"Heart failure with recovered ejection fraction: a distinct clinical entity","volume":"17","author":"Punnoose","year":"2011","journal-title":"J Card Fail"},{"key":"10.1016\/j.jjcc.2023.07.019_bb0505","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0140-6736(18)32484-X","article-title":"Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial","volume":"393","author":"Halliday","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jjcc.2023.07.019_bb0510","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/ejhf.1103","article-title":"Evolving concepts in dilated cardiomyopathy","volume":"20","author":"Merlo","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jjcc.2023.07.019_bb0515","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1093\/eurjhf\/hfq093","article-title":"Prognostic impact of familial screening in dilated cardiomyopathy","volume":"12","author":"Moretti","year":"2010","journal-title":"Eur J Heart Fail"}],"container-title":["Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0914508723001855?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0914508723001855?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T13:10:11Z","timestamp":1760274611000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0914508723001855"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":103,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S0914508723001855"],"URL":"https:\/\/doi.org\/10.1016\/j.jjcc.2023.07.019","relation":{},"ISSN":["0914-5087"],"issn-type":[{"value":"0914-5087","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Implementation of evidence-based heart failure management: Regional variations between Japan and the USA","name":"articletitle","label":"Article Title"},{"value":"Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jjcc.2023.07.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Japanese College of Cardiology. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}